A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit ...

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination ...

Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...